Definium Therapeutics (DFTX) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Definium Therapeutics (NASDAQ: DFTX) in the last few weeks:

• 4/23/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $40.00 price target on the stock.
• 4/22/2026 – Definium Therapeutics had its price target raised by Leerink Partners from $23.00 to $30.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – Definium Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/16/2026 – Definium Therapeutics was given a new $30.00 price target by Stifel Nicolaus. They now have a “buy” rating on the stock.
• 4/16/2026 – Definium Therapeutics was given a new $38.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 4/10/2026 – Definium Therapeutics is now covered by Piper Sandler. They set an “overweight” rating and a $49.00 price target on the stock.
• 4/9/2026 – Definium Therapeutics was upgraded by Piper Sandler to “strong-buy”.
• 3/2/2026 – Definium Therapeutics had its price target raised by HC Wainwright from $55.00 to $70.00. They now have a “buy” rating on the stock.

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.